Skip to main content
. 2022 Sep 1;26(5):347–355. doi: 10.4196/kjpp.2022.26.5.347

Fig. 3. ATF4 transcriptionally activates FGF21 in HASMCs.

Fig. 3

(A–C) RT-qPCR and Western blotting of ATF4 expression in HASMCs treated with different concentrations (0–100 nM) of Ang-II. (D, E) JASPAR website for prediction of ATF4 binding site in FGF21 promoter region. (F) ChIP assay for identifying the binding relation between ATF4 and FGF21 promoter. (G, H) Western blotting of ATF4 and FGF21 protein expression in ATF4-depleted HASMCs. (I) Luciferase reporter assay for identifying the binding relation between ATF4 and FGF21 promoter. ATF4, activating transcription factor 4; FGF21, fibroblast growth factor 21; HASMCs, human aortic vascular smooth muscle cells; RT-qPCR, real time quantitative polymerase chain reaction; Ang-II, angiotensin II; TFBS, transcription factor binding site; TSS, transcription start site; ChIP, chromatin immunoprecipitation. *p < 0.05, **p < 0.01, ***p < 0.001.